Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years.

Details

Serval ID
serval:BIB_39DB29D8297F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years.
Journal
The Journal of infectious diseases
Author(s)
Schoepf I.C., Thorball C.W., Ledergerber B., Kootstra N.A., Reiss P., Raffenberg M., Engel T., Braun D.L., Hasse B., Thurnheer C., Marzolini C., Seneghini M., Bernasconi E., Cavassini M., Buvelot H., Arribas J.R., Kouyos R.D., Fellay J., Günthard H.F., Tarr P.E.
ISSN
1537-6613 (Electronic)
ISSN-L
0022-1899
Publication state
Published
Issued date
04/05/2022
Peer-reviewed
Oui
Volume
225
Number
9
Pages
1581-1591
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
In people with human immunodeficiency virus (PWH), long-term telomere length (TL) change without/with suppressive antiretroviral therapy (ART) and the contribution of genetic background to TL are incompletely understood.
We measured TL change in peripheral blood mononuclear cells by quantitative polymerase chain reaction in 107 Swiss HIV Cohort Study participants with longitudinal samples available both before and during suppressive ART. We applied mixed-effects multilevel regression to obtain uni-/multivariable estimates for longitudinal TL dynamics including age, sex, and CD4/CD8 ratio. We assessed the effect of (1) individual antiretrovirals and (2) an individual TL-polygenic risk score ([TL-PRS] based on 239 single-nucleotide polymorphisms) on TL in 798 additional participants from our previous longitudinal studies.
During untreated human immunodeficiency virus (HIV) infection (median observation, 7.7; interquartile range [IQR], 4.7-11] years), TL declined significantly (median -2.12%/year; IQR, -3.48% to -0.76%/year; P = .002). During suppressive ART (median observation, 9.8; IQR, 7.1-11.1 years), there was no evidence of TL decline or increase (median + 0.54%/year; IQR, -0.55% to + 1.63%/year; P = .329). The TL-PRS contributed to TL change (global P = .019) but particular antiretrovirals did not (all P > .15).
In PWH, TL is associated with an individual PRS. Telomere length declined significantly during untreated chronic HIV infection, but no TL change occurred during suppressive ART.
Keywords
Anti-Retroviral Agents/therapeutic use, Cohort Studies, HIV/genetics, HIV Infections, Humans, Leukocytes, Mononuclear, Longitudinal Studies, Telomere/genetics, HIV, antiretroviral therapy, longitudinal study, polygenic risk score, telomere length
Pubmed
Web of science
Create date
20/12/2021 13:04
Last modification date
28/05/2022 6:34
Usage data